Kolon Life Science Inc
KOSDAQ:102940
Intrinsic Value
KOLON Life Science, Inc. engages in the manufacture and sale of pharmaceuticals and environment materials. [ Read More ]
The intrinsic value of one Kolon Life Science Inc stock under the Base Case scenario is 17 368.04 KRW. Compared to the current market price of 22 100 KRW, Kolon Life Science Inc is Overvalued by 21%.
Valuation Backtest
Kolon Life Science Inc
Run backtest to discover the historical profit from buying and selling Kolon Life Science Inc stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Kolon Life Science Inc
| Current Assets | 105B |
| Cash & Short-Term Investments | 7.5B |
| Receivables | 25.6B |
| Other Current Assets | 71.9B |
| Non-Current Assets | 204.4B |
| Long-Term Investments | 79.9B |
| PP&E | 123.1B |
| Intangibles | 332.5m |
| Other Non-Current Assets | 996m |
| Current Liabilities | 128.3B |
| Accounts Payable | 11.5B |
| Accrued Liabilities | 4.4B |
| Short-Term Debt | 97.3B |
| Other Current Liabilities | 15.2B |
| Non-Current Liabilities | 43.4B |
| Long-Term Debt | 10.2B |
| Other Non-Current Liabilities | 33.3B |
Earnings Waterfall
Kolon Life Science Inc
|
Revenue
|
124.6B
KRW
|
|
Cost of Revenue
|
-112.2B
KRW
|
|
Gross Profit
|
12.4B
KRW
|
|
Operating Expenses
|
-36.5B
KRW
|
|
Operating Income
|
-24.1B
KRW
|
|
Other Expenses
|
-6.6B
KRW
|
|
Net Income
|
-30.7B
KRW
|
Free Cash Flow Analysis
Kolon Life Science Inc
Profitability Score
Profitability Due Diligence
Kolon Life Science Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
Kolon Life Science Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Kolon Life Science Inc's solvency score is 28/100. The higher the solvency score, the more solvent the company is.
Score
Kolon Life Science Inc's solvency score is 28/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Kolon Life Science Inc
According to Wall Street analysts, the average 1-year price target for Kolon Life Science Inc is 133 333 KRW .
Shareholder Return
Price
Kolon Life Science Inc
| Average Annual Return | 7.71% |
| Standard Deviation of Annual Returns | 54.62% |
| Max Drawdown | -66% |
| Market Capitalization | 252.2B KRW |
| Shares Outstanding | 11 412 400 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
KOLON Life Science, Inc. engages in the manufacture and sale of pharmaceuticals and environment materials. The company is headquartered in Seoul, Seoul and currently employs 451 full-time employees. The company went IPO on 2009-04-07. The firm operates its business under two segments. The Chemical Business segment produces and sells raw drug products, which are the raw materials of new drugs and generic drugs, antibacterial agents that suppress bacterial growth, water treatment agents for environmental purification, and functional material products for cosmetics. The Bio Business segment manufactures and sells bio new medicines based on cell gene therapy products.
Contact
IPO
Employees
Officers
The intrinsic value of one Kolon Life Science Inc stock under the Base Case scenario is 17 368.04 KRW.
Compared to the current market price of 22 100 KRW, Kolon Life Science Inc is Overvalued by 21%.
You don't have any saved screeners yet
